Volume 3.00 | Jan 6

Mammary Cell News 3.00 January 6, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors  ShareThis
Expression of BRCA1 is commonly decreased in sporadic breast tumors, and this correlates with poor prognosis of breast cancer patients. Here, researchers show that BRCA1 transcripts are selectively enriched in the Argonaute/miR-182 complex and miR-182 downregulates BRCA1 expression. [Mol Cell]

ON107-MammaryWallchart-645x110_CTA_WhatsOYW



SPECIAL FEATURE

Facebook  Cell Therapy News is now on Facebook. Join us!

Twitter Follow us on Twitter! @MammaryCell

Interested in recruiting talented individuals? Post your career opportunities in Mammary Cell News at no cost. Contact us at in[email protected]



SCIENCE NEWS

Experimental Drug Helps Fight Aggressive Breast Cancer: Report
In this study, the experimental drug iniparib not only shrank tumors and increased the time they took to progress, but also surprised researchers by prolonging survival in women with triple-negative breast cancer. [Press release from MedlinePlus discussing online prepublication in the New England Journal of Medicine]

Risk of Breast Cancer Recurrence May Depend on Treating Surgeon
Ductal carcinoma in situ is typically treated with either breast-conserving surgery – with or without follow-up radiation – or mastectomy. The treatment choice depends on clinical factors, the treating surgeon, and patient preferences. Long-term health outcomes (disease-free survival) depend on the treatments received. According to a study, however, health outcomes also are associated with the treating surgeon. [The Journal of the National Cancer Institute Press Release]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies
 
 
WATCH PROCEDURE NOW STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Stromal Retinoic Acid Receptor Beta Promotes Mammary Gland Tumorigenesis
Retinoic acid is a potent differentiation and antiproliferative agent of breast cancer cells, and one of its receptors, retinoic acid receptor beta (RARbeta), has been proposed to act as a tumor suppressor. In contrast, researchers report herein that inactivation of Rarb in the mouse results in a protective effect against ErbB2-induced mammary gland tumorigenesis. [Proc Natl Acad Sci USA]

TGF-Beta Promotion of Gli2 Induced PTHrP Expression Is Independent of Canonical Hedgehog Signaling
In this study, researchers tested the hypothesis that Hedgehog inhibition in bone metastatic breast cancer would decrease parathyroid hormone-related protein (PTHrP) expression and therefore osteolytic bone destruction. [Cancer Res]

Ultrasensitive Electrochemical Immunoassay for BRCA1 Using BMIM-BF4-Coated SBA-15 as Labels and Functionalized Graphene as Enhancer
In this study, researchers designed a new label and fabricated a novel sandwich-type electrochemical immunoassay for the ultrasensitive detection of BRCA1. [Biomaterials]

Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay Between p53 and CD44
Breast tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological fracture. Here, researchers report that simvastatin acts as an inhibitor of osteolysis in a mouse model of breast cancer skeletal metastasis of human mammary cancer cell MDA-MB-231, which expresses the mutant p53R280K. [J Biol Chem]

Extracellular Signal-Regulated Kinase 8 (Erk8) Controls Estrogen-Related Receptor Alpha (ERRAlpha) Cellular Localization and Inhibits its Transcriptional Activity
Based on the well-established positive role of ERRalpha in mammary carcinogenesis, researchers demonstrate that Erk8 is able to counteract, in immortalized human mammary cells, ERRalpha activation induced by the EGF receptor pathway, often deregulated in breast cancer. [J Biol Chem]

The Anti-Cancer Effects of (-)-Epigalocathine-3-Gallate on the Signaling Pathways Associated with Membrane Receptors in MCF-7 Cells
(-)-Epigallocatechin-3-gallate (EGCg) has been implicated in cancer chemo-prevention in studies using many different kinds of cancer cells. The present study measured cell viability, osteopontin secretion, fatty acid synthase expression, and cytosolic Ca2+ and verified the anti-cancer activities of EGCg in MCF-7 human breast cancer cells. [J Cell Physiol]

Dynamic Interaction Between Breast Cancer Cells and Osteoblastic Tissue: Comparison of Two and Three Dimensional Cultures
Breast cancer cell colonization of osteoblast monolayers grown in standard tissue culture (2D) is compared to colonization of a multi-cell-layer osteoblastic tissue (3D) grown in a specialized bioreactor. [J Cell Physiol]

Unravelling the Mystery of Stem/Progenitor Cells in Human Breast Milk
Researchers identified markers associated with hemopoietic, mesenchymal and neuro-epithelial lineages in the cellular component of human breast milk. [PLoS One]

CLINICAL RESEARCH

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
Researchers conducted an open-label, phase II study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. [N Engl J Med]

Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers. [J Clin Oncol]

In Patients Younger Than Age 55 Years with Lymph Node-Negative Breast Cancer, Proliferation by Mitotic Activity Index Is Prognostically Superior to Adjuvant!
Researchers compared the accuracy of the online program Adjuvant!, the Norwegian Breast Cancer Group (NBCG) guidelines, and the proliferation factor mitotic activity index in patients with lymph node-negative disease. [J Clin Oncol]

Gene Pathways Associated with Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
Researchers hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers. [J Natl Cancer Inst]

Associations of Breast Cancer Risk Factors with Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
Researchers pooled tumor marker and epidemiological risk factor data from 35???568 invasive breast cancer case patients from 34 studies participating in the Breast Cancer Association Consortium. Logistic regression models were used in case-case analyses to estimate associations between epidemiological risk factors and tumor subtypes, and case-control analyses to estimate associations between epidemiological risk factors and the risk of developing specific tumor subtypes in 12 population-based studies. [J Natl Cancer Inst]

INDUSTRY NEWS

Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology
Metamark Genetics, Inc., a privately held oncology-focused molecular diagnostics company, and HistoRx, Inc., a diagnostics company developing tissue-based diagnostic solutions to advance individualized patient care, announced a multi-year licensing agreement. [Metamark Genetics, Inc. Press Release]

Advanced Cell Technology Secures $25 Million Funding Commitment
Advanced Cell Technology, Inc. announced that it has entered into a $25 million non-convertible stock purchase agreement with Socius CG II, Ltd., a subsidiary of Socius Capital Group. [Advanced Cell Technology, Inc. Press Release]

Pfizer Ordered to Pay $1.5 Million in Prempro Damages
Pfizer Inc. must pay $1.5 million in damages to a pharmacist who developed breast cancer after taking one of the company’s menopause drugs, a jury in Puerto Rico ruled. [Bloomberg]



POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)



EVENTS

Visit our events page  to stay up to date with the latest events in the mammary cell community.


JOB OPPORTUNITIES

Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!



Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us